A 62-year-old man with hypertension and benign prostatic hyperplasia (BPH) is on atenolol 50 mg daily. His blood pressure remains suboptimally controlled (156/94 mmHg), and he has moderate LUTS (IPSS score 18). His cardiologist adds an alpha blocker to his regimen. Within 48 hours, the patient experiences severe dizziness, fatigue, and a syncopal episode. Blood pressure supine: 138/86 mmHg; standing: 104/62 mmHg. Serum creatinine: 1.2 mg/dL; electrolytes normal. Which alpha blocker was MOST likely prescribed, and what is the primary pharmacodynamic interaction?

Explanation

## Clinical Context: Drug-Drug Interaction The patient is on a **beta-blocker (atenolol)** and develops **severe orthostatic hypotension** within 48 hours of adding an alpha blocker. This is a **classic pharmacodynamic interaction**, not a metabolic one. ## Mechanism of Orthostatic Hypotension with Combined Therapy ```mermaid flowchart TD A[Alpha Blocker + Beta-Blocker]:::action --> B[α1-mediated vasodilation]:::outcome A --> C[Loss of reflex tachycardia]:::outcome B --> D[Reduced peripheral vascular resistance]:::outcome C --> E[Impaired compensatory HR increase]:::outcome D --> F[Decreased cardiac output on standing]:::outcome E --> F F --> G[Severe orthostatic hypotension & syncope]:::urgent ``` ## Why Doxazosin (Not Terazosin or Selective Agents)? ### Doxazosin: Non-selective α1 blockade - Blocks both **α1A** (prostate) and **α1B** (vascular) receptors - Causes marked **peripheral vasodilation** - Reduced peripheral vascular resistance (SVR ↓) - Combined with beta-blocker: **no reflex tachycardia** to compensate ### Why NOT Tamsulosin or Alfuzosin? - **Selective α1A blockade** → minimal vascular effects - Even with beta-blocker co-administration, orthostatic drop is mild - Would NOT cause syncope within 48 hours in this clinical context ### Why NOT Terazosin? - Terazosin is also non-selective, BUT: - Shorter half-life (12 hours) → slower accumulation - Requires gradual titration (start 0.5 mg) → slower onset of side effects - Doxazosin (half-life 22 hours) reaches steady-state faster and causes more rapid symptom onset ## Key Point: Pharmacodynamic Interaction Mechanism 1. **Alpha blocker** → vasodilation (↓ SVR, ↓ venous return) 2. **Beta-blocker** → blunts reflex tachycardia and inotropic response 3. **Combined effect** → inadequate compensation for postural blood pressure drop 4. **Result** → severe orthostatic hypotension, syncope **High-Yield:** This is NOT a CYP450 interaction; it is a **direct pharmacodynamic antagonism** of the sympathetic compensatory mechanisms. ## Clinical Pearl: Risk Stratification **Mnemonic — "DASH" for high-risk combinations:** - **D**oxazosin/Doxazosin + beta-blockers = ↑↑ orthostatic risk - **A**lfuzosin/Tamsulosin + beta-blockers = ↓ orthostatic risk (selective) - **S**tart low, titrate slow (especially non-selective agents) - **H**ydration and patient education on postural changes ## Management 1. **Immediate:** Switch to **selective α1A blocker** (tamsulosin or alfuzosin) 2. **Alternative:** Reduce doxazosin dose or discontinue beta-blocker if BP control allows 3. **Patient counseling:** Rise slowly from supine/seated position; increase fluid intake